Staphylococcus Pseudintermedius Small Molecule Treatment


The Problem:

Staphylococcus pseudintermedius causes canine pyoderma (skin infection) and is frequently resistant to almost all antibiotics. Pyoderma represents nearly 500 million dollars in annual veterinary care, with an average visit cost of $175.  S. pseudintermedius produces proteins that shield the bacteria from their host’s immune defense.


The Solution:

Researchers at the University of Tennessee have developed a small molecule therapy that inhibits key bacterial enzymatic activity.  It leaves S. pseudintermedius vulnerable to killing and clearance by the host immune system.



       The compound efficiently inhibits a key enzyme function.

       Significant target engagement has been demonstrated.

       It is effective against all major strains of S. pseudintermedius affecting dogs in the United States.

       Compound activity has been demonstrated in both enzyme assays and biological assays.


 The Inventor



Dr. Stephen A Kania is a Professor in the Department of Comparative Medicine at UTK.  He received his Ph.D. degree in Molecular Microbiology from the University of Florida.  His research interest is the characterization of methicillin resistant S. Pseudintermedius.  He studies S. pseudintermedius  genomics, molecular epidemiology, immunology and proteomics.

Patent Information: